SYLVESTER, Richard

Email Alert RSS Feed

Profile

Full Name
SYLVESTER, Richard
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Results 1-20 of 36 (Search time: 0.005 seconds).

show all
Issue DateTitleContributor(s)TypeCat.
12013Professor Maurice Staquet, MD, MS (1930-2013) In MemoriamDuez, Nicole; Eeckhoudt, Dominique; Kirkpatrick, Anne; Solbu, Gabriel; Suciu, Stefan; SYLVESTER, Richard; Van Glabbeke, Martine; BUYSE, Marc; Dalesio, Otilia; Renard, Josette; Rotmensz, NicoleJournal ContributionM
22009Validation of prognostic indices using the frailty modelLEGRAND, Catherine; DUCHATEAU, Luc; JANSSEN, Paul; Ducrocq, V.; SYLVESTER, RichardJournal ContributionA1
32006Heterogeneity in disease free survival between centers: lessons learned from an EORTC breast cancer trialLEGRAND, Catherine; DUCHATEAU, Luc; SYLVESTER, Richard; JANSSEN, Paul; van der Hage, JA; van de Velde, CJH; Therasse, PJournal ContributionA1
42005A Bayesian approach to jointly estimate centre and treatment by centre heterogeneity in a proportional hazards modelLEGRAND, Catherine; Ducrocq, V; JANSSEN, Paul; SYLVESTER, Richard; DUCHATEAU, LucJournal ContributionA1
52003Does it matter where you are treated? A treatment outcome study based on clinical trial dataLEGRAND, Catherine; DUCHATEAU, Luc; SYLVESTER, Richard; JANSSEN, PaulJournal ContributionM
62003The side effects of Bacillus Calmette-Guerin in the treatment of TaT1 bladder cancer do not predict its efficacy: results form a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trialSYLVESTER, Richard; van der Meijden, A.P.M.; Oosterlinck, W.; Hoeltl, W.; Bono, A.Journal ContributionA1
72002The shared frailty model and the power for heterogeneity tests in multicenter trialsDUCHATEAU, Luc; JANSSEN, Paul; LEGRAND, Catherine; LINDSEY, Patrick; NGUTI, Rosemary; SYLVESTER, RichardJournal ContributionA1
82002Multicollinearity in prognostic factor analysis using the EORTC QLQ-C30: identification and impact on model selectionVAN STEEN, Kristel; Curran, Desmond; Kramer, Jocelyn; MOLENBERGHS, Geert; Van Vreckem, Ann; SYLVESTER, RichardJournal ContributionA1
92002Variability in the recurrence rate of first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis or seven EORTC studiesBrausi, M.; Collette, L.; Kurth, K.; van der Meijden, A.P.; Oosterlinck, W.; Witjes, W.A.; Newling, D.; Bouffioux, Christophe; SYLVESTER, RichardJournal ContributionA1
102002Analysing longitudinal continuous quality of life data with dropoutCurran, Desmond; MOLENBERGHS, Geert; Aaronson, N.; Fossa, S.; SYLVESTER, RichardJournal ContributionA1
112002Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized trialsSYLVESTER, Richard; van der Meijden, A.P.M.; Lamm, D.L.Journal ContributionA1
122002Treatment outcome studies: pitfalls in curent methods and practiceLEGRAND, Catherine; SYLVESTER, Richard; DUCHATEAU, Luc; JANSSEN, Paul; Therasse, PatrickJournal ContributionA1
131999Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: r=the final results of a European organization for research in cancer therapy genitourinary group trialde Reijke, T.M.; Keuppens, F.I.; Whelan, P.; Kliment, J.; Robinson, M.R.G.; Rea, L.A.; SYLVESTER, RichardJournal Contribution
141999Impact of the treating institution on survival of patients with "poor progosis" metastatic nonseminomaCollette, L.; SYLVESTER, Richard; Stenning, S.P.; Fossa, S.D.; Mead, G.M.; de Wit, R.; de Mulder, P.H.M.; Neymark, N.; Lallemand, E.; Kaye, S.B.Journal Contribution
151998Serum alpha-fetoprotein surge after the iniation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significanceSYLVESTER, Richard; de Wit, R.; Collette, L.; de Mulder, P.H.M.; Sleijfer, D.T.; ten Bokkel Huinink, W.W.; Kaye, S.B.; van Oosterom, A.T.; Boven, E.; Stoter, G.Journal Contribution
161998Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer studyKaye, S.B.; Mead, G.M.; Fossa, S.; Cullen, M.; de Wit, R.; Bodrogi, I.; van Groeningen, C.; SYLVESTER, Richard; Collette, L.; Stenning, S.; de Prijck, L.; Lallemand, E.Journal Contribution
171998Four cycles of BEP vs four cycles of VIR in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Groupde Wit, R.; Stoter, G.; Sleijfer, D.T.H.; Neijt, J.P.; ten Bokkel Huinink, W.W.; de Prijck, L.; Collette, L.; SYLVESTER, RichardJournal Contribution
181998Identifying the types of missingness in quality of life data from clinical trialsCurran, Desmond; Bacchi, M.; Hsu Schmitz, Shu-Fang; MOLENBERGHS, Geert; SYLVESTER, RichardJournal Contribution
191997An introduction to the statistical design of phase III cancer clinical trialsSYLVESTER, RichardJournal Contribution
201997Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection aloneKurth, K.; Tunn, U.; Ay, R.; Schroder, F.; Pavone-Macaluso, M.; Debruyne, F.; ten Kate, F.; de Pauw, M.; SYLVESTER, RichardJournal Contribution
show all